Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors

Tailoring antiplatelet therapy based on CYP2C19 pharmacogenetic (PGx) testing can improve cardiovascular outcomes and potentially reduce healthcare costs in patients on a P2Y(12)-inhibitor regime with prasugrel or ticagrelor. However, ubiquitous adoption—particularly in an outpatient setting—remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Levens, Amar D., den Haan, Melina C., Jukema, J. Wouter, Heringa, Mette, van den Hout, Wilbert B., Moes, Dirk Jan A. R., Swen, Jesse J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048116/
https://www.ncbi.nlm.nih.gov/pubmed/36980851
http://dx.doi.org/10.3390/genes14030578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048116/
https://www.ncbi.nlm.nih.gov/pubmed/36980851
http://dx.doi.org/10.3390/genes14030578

Ejemplares similares